LGMD2C

Clinical trials for LGMD2C explained in plain language.

Never miss a new study

Get alerted when new LGMD2C trials appear

Sign up with your email to follow new studies for LGMD2C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1

Gene therapy hope for kids with rare muscle-wasting disease

Disease control Ongoing

This early-stage trial tests a single intravenous dose of a gene therapy (ATA-200) in 4 children aged 6-12 with limb-girdle muscular dystrophy type 2C/R5 (LGMD2C), a rare genetic muscle-weakening condition. The goal is to see if the treatment is safe and tolerable by delivering a…

Matched conditions: LGMD2C

Phase: PHASE1 • Sponsor: Atamyo Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 09:00 UTC

LGMD2C

Get alerted when new LGMD2C trials appear

Gene therapy hope for kids with rare muscle-wasting disease